Roche IL-6 is the first immunoassay approved to aid sepsis diagnosis in newborns
18 oct. 2023 01h03 HE
|
F. Hoffmann-La Roche Ltd
Neonatal sepsis is a leading cause of death for newbornsTesting IL-6 can indicate a neonatal sepsis infection earlier than other biomarkersEarlier diagnosis of neonatal sepsis can lead to improved...
Roche’s Alecensa reduces the risk of disease recurrence or death by an unprecedented 76% in people with ALK-positive early-stage non-small cell lung cancer
18 oct. 2023 01h00 HE
|
F. Hoffmann-La Roche Ltd
These Phase III data are the first and only to show an improvement in disease-free survival in early-stage resected ALK-positive non-small cell lung cancer (NSCLC) With about one in two people with...
Late-breaking data for Roche’s BTK inhibitor fenebrutinib show brain penetration and significant reduction in lesions in patients with relapsing multiple sclerosis
13 oct. 2023 09h30 HE
|
F. Hoffmann-La Roche Ltd
New data from Phase II FENopta study in relapsing multiple sclerosis (RMS) show fenebrutinib crosses the blood-brain barrier with the potential to act directly on the chronic inflammation related to...
New data for Roche’s OCREVUS show that after 10 years of treatment 77% of people with relapsing multiple sclerosis were free from disability progression and 92% continue to walk unaided
12 oct. 2023 01h00 HE
|
F. Hoffmann-La Roche Ltd
10-year efficacy data highlight OCREVUS’ impact on preventing disability progression and maintaining mobility in both relapsing and progressive forms of multiple sclerosis (MS)10-year safety data from...
Roche’s OCREVUS twice-yearly, 10-minute subcutaneous injection was non-inferior to intravenous infusion and provided near-complete suppression of brain lesions
11 oct. 2023 02h00 HE
|
F. Hoffmann-La Roche Ltd
Late-breaking Phase III results show subcutaneous injection was non-inferior to intravenous infusion based on OCREVUS levels in the blood over 12 weeks OCREVUS subcutaneous injection was comparable to...
Roche’s Vabysmo maintained vision improvements with extended treatment intervals up to four months for people with retinal vein occlusion (RVO) in phase III studies
10 oct. 2023 01h00 HE
|
F. Hoffmann-La Roche Ltd
Vabysmo showed robust and sustained retinal drying up to 72 weeks and a safety profile consistent with previous studiesRegulatory applications for Vabysmo in RVO are under review by health authorities...
Majority of newborn babies with spinal muscular atrophy (SMA) treated with Roche’s Evrysdi able to sit independently after 1 year of treatment
04 oct. 2023 01h00 HE
|
F. Hoffmann-La Roche Ltd
RAINBOWFISH study met its primary endpoint with 80% of babies sitting without support for at least five seconds after 1 year of Evrysdi treatment – without treatment these babies would never be able...
Roche to present new key clinical and real-world data at ECTRIMS-ACTRIMS 2023 showcasing strength of long-term outcomes in MS and NMOSD
02 oct. 2023 01h00 HE
|
F. Hoffmann-La Roche Ltd
Late-breaking results from Phase III trial of OCREVUS (ocrelizumab) subcutaneous injection and Phase II trial of BTK inhibitor fenebrutinib in multiple sclerosis (MS) will be presented10-year OCREVUS...
Roche and Alnylam report positive topline results from Phase 2 study KARDIA-1 of zilebesiran, an investigational RNAi therapeutic in development to treat hypertension in patients at high risk of cardiovascular disease
07 sept. 2023 07h00 HE
|
F. Hoffmann-La Roche Ltd
Zilebesiran met primary endpoint demonstrating greater than 15 mmHg reduction of systolic blood pressure at three months of treatment compared to placebo Study met key secondary endpoints showing...
Roche’s Alecensa delivers unprecedented Phase III results for people with ALK-positive early-stage lung cancer
01 sept. 2023 01h00 HE
|
F. Hoffmann-La Roche Ltd
ALINA data demonstrate Alecensa reduces disease recurrence in the early setting for people with ALK-positive non-small cell lung cancer (NSCLC), building on its long-established benefit in the...